Ferrous Ascorbate
drugOn this page
Also known as AscoferCompleferIron(ii) ascorbateJ290.062IL-ascorbic acidiron complexNedifer
Summary
Ferrous Ascorbate (CHEMBL3707305) is a phase-3 clinical-stage small molecule (ATC B03AA10); indicated across 1 condition including anemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: B03AA10
- Indications: 1 condition
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3707305 |
| Name | Ferrous Ascorbate |
| Type | Small molecule |
| Max phase | 3 |
| ATC | B03AA10 |
Also known as: Ascofer, Complefer, Ferrous ascorbate, Iron(ii) ascorbate, J290.062I, L-ascorbic acid, iron complex, Nedifer, FERROUS ASCORBATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 3 | MONDO:0002280 | EFO:0004272 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01160198 | PHASE3 | COMPLETED | A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate. |
| NCT05957328 | PHASE3 | UNKNOWN | A Study to Compare Liposomal Iron With Ferrous Ascorbate in the Treatment of Iron Deficiency Anemia in Children |
| NCT06303531 | Not specified | UNKNOWN | Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia